It’s worth reviewing this thread.
Also below is my post from May when SPL was 72 cents. I still see no reason why Starpharma will not fall out of the ASX300 next rebalance.
”This is heading to the 60s for sure. IMO the market does not believe the Starpharma story and Jackie Fairley’s blah blah blah anymore. Grinding lower. Stop losses. Tax loss selling. Stop losses. Institutions quietly lightening IMO due to expected falling out of ASX300 next rebalance. Stop losses. Will likely see mid to low 60’s.” ~
@sarge17P.S. It’s quite comical that after ALL the delays and excuses for the DEP-Docetaxel Phase 2 trial results being delayed, this latest delay, and pending recruitment of even more patients to fish for results in another drug combination, some posters are saying that this is a good thing because the trial is going so well. Major lol. Give me a break. Wake up and smell the coffee IMO.
